Intérêt d'un traitement par omalizumab dans le cadre d'une immunothérapie spécifique. Recueil d'expérience et analyse de la littérature

Translated title of the contribution: The interest of treatment with omalizumab in the framework of specific immunotherapy

J. P. Oster, F. Lavaud, A. Bentaleb, Y. Bloch, J. L. Bourrain, P. Carré, G. Devouassoux, G. Newinger, M. Verdaguer, F. de Blay

    Research output: Contribution to journalArticlepeer-review

    3 Scopus citations


    Our aim was to assess the eventual impact of pretreatment with omalizumab on the tolerance and efficacy of specific immunotherapy (SIT). Based on a collection of experiences, we report observations on 10groups of patients who have received that therapeutic combination. Six of these observations involved patients sensitized to bees; their SIT was stopped because of problems with tolerance. In these six observations, different sorts of pretreatment with omalizumab was considered effective, which allowed bee venom SIT to be started and then maintained. While no randomized clinical trial has evaluated the effect of omalizumab treatment on tolerance to hymenoptera venoms, a number of published reports emphasize the efficacy of this pretreatment in improving tolerance to this SIT. Four observations concerned patients with severe allergic asthma due to sensitization to mites. In three of these observations, the association of omalizumab and mite SIT was considered effective in terms of control of the asthma and tolerance to the SIT; the combination was not considered effective in the fourth case. This collection of observations and an analysis of the literature have allowed us to emphasize the role of pretreatment with omalizumab in improving tolerance to SIT with hymenoptera venom. In the context of respiratory allergies, there are arguments for the combination of these two therapeutic modes in spite of the difficulty of applying it, especially in the case of severe asthma.

    Translated title of the contributionThe interest of treatment with omalizumab in the framework of specific immunotherapy
    Original languageFrench
    Pages (from-to)347-355
    Number of pages9
    JournalRevue Francaise d'Allergologie
    Issue number5
    StatePublished - 1 Sep 2014


    • Allergen immunotherapy
    • Asthma
    • Hymenoptera venom allergy
    • Mite allergy
    • Omalizumab

    ASJC Scopus subject areas

    • Immunology and Allergy


    Dive into the research topics of 'The interest of treatment with omalizumab in the framework of specific immunotherapy'. Together they form a unique fingerprint.

    Cite this